搜尋
Adagene Inc
ADAG添加自選
3.750USD
+0.020+0.54%
收盤 07-31 16:00（美東）報價延遲15分鐘
247.69M總市值
虧損本益比TTM
關於 Adagene Inc 公司
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Adagene Inc簡介
公司代碼ADAG
公司名稱Adagene Inc
上市日期Feb 09, 2021
CEOLuo (Peter)
員工數量138
證券類型Depository Receipt
年結日Feb 09
公司地址4F, Building C14, No. 218, Xinghu Street
城市SUZHOU
上市交易所NASDAQ OMX - NASDAQ BASIC
國家China
郵編- -
電話8651287773632
網址https://www.adagene.com/
公司代碼ADAG
上市日期Feb 09, 2021
CEOLuo (Peter)
Adagene Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.60M
+11.48%
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Wang (Ron) Yuren, Ph.D.
Dr. Wang (Ron) Yuren, Ph.D.
Head of Portfolio Management
Head of Portfolio Management
--
--
Dr. Shang Jin
Dr. Shang Jin
Senior Vice President of Global Regulatory Affairs
Senior Vice President of Global Regulatory Affairs
--
--
Dr. Zheng Songmao
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
--
--
Dr. Zha Jiping, Ph.D.
Dr. Zha Jiping, Ph.D.
Executive Vice President of Clinical Development
Executive Vice President of Clinical Development
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
Ms. Ami Knoefler
Ms. Ami Knoefler
Vice President of Investor Relations and Corporate Communications
Vice President of Investor Relations and Corporate Communications
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.60M
+11.48%
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Wang (Ron) Yuren, Ph.D.
Dr. Wang (Ron) Yuren, Ph.D.
Head of Portfolio Management
Head of Portfolio Management
--
--
Dr. Shang Jin
Dr. Shang Jin
Senior Vice President of Global Regulatory Affairs
Senior Vice President of Global Regulatory Affairs
--
--
常見問題
Adagene Inc的前五大股東是誰？
Adagene Inc的前五大股東如下：Dr. Peter (Peizhi) Luo, Ph.D.
有多少機構持有Adagene Inc(ADAG)的股份？
截至2026Q1，共有38家機構持有Adagene Inc的股份，合計持有的股份價值約為13.55M，占公司總股份的20.51% 。與2025Q4相比，機構持股有所增加，增幅為-2119805.00。